title: High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.
abstract: OBJECTIVE
  To assess the outcome of high-dose therapy with autologous stem-cell support in patients with histologic transformation of low-grade follicular non-Hodgkin's lymphoma (NHL) and identify significant prognostic factors, as well as to compare survival of these patients with that of patients with matched low-grade and de novo high- or intermediate-grade NHL undergoing the same procedure.
  
  
  METHODS
  Fifty patients with transformed low-grade NHL have been reported to the European Bone Marrow Transplant registry. Outcome from high-dose therapy and significant prognostic factors were analyzed. Their survival was also compared with that of 200 patients with matched low-grade NHL and 200 patients with matched de novo high- or intermediate-grade NHL by a case-matched analysis.
  
  
  RESULTS
  The procedure-related death rate among the 50 transformed NHL patients was 18%. Overall survival (OS) and progression-free survival (PFS) rates were 51% and 30% at 5 years, respectively. Median PFS time was 13 months. Raised lactate dehydrogenase levels at transformation (P =.0031) was identified as the only adverse significant predictor of PFS on multivariate analysis. A subgroup of patients with residual chemosensitive disease who attained complete remission after high-dose therapy had the best outcome, with an OS at 5 years of 69%. A comparison with matched patients with low-grade disease and with de novo high- or intermediate-grade lymphoma showed no significant difference in OS (P =.939 and P =.438, respectively).
  
  
  CONCLUSIONS
  Patients with chemosensitive transformed lymphoma should be seriously considered for high-dose therapy and autologous stem-cell support.
authors.affiliation: Department of Hematology, University College Hospital, London, United Kingdom. catherine.williams@christie-tr.nwest.nhs.uk
authors.forename: C D
authors.initials: CD
authors.lastname: Williams
authors.forename: C N
authors.initials: CN
authors.lastname: Harrison
authors.forename: T A
authors.initials: TA
authors.lastname: Lister
authors.forename: A J
authors.initials: AJ
authors.lastname: Norton
authors.forename: A K
authors.initials: AK
authors.lastname: Blystad
authors.forename: B
authors.initials: B
authors.lastname: Coiffier
authors.forename: G
authors.initials: G
authors.lastname: Taghipour
authors.forename: N
authors.initials: N
authors.lastname: Schmitz
authors.forename: A H
authors.initials: AH
authors.lastname: Goldstone
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D016022:Case-Control Studies; D002471:Cell Transformation, Neoplastic / Q000473:pathology; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015996:Survival Rate